All In Biotech

Drug Trial Radar · NCT06049810

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Randomized Withdrawal and Retreatment Phase III Clinical Trial Evaluating the Efficacy and Safety of Subcutaneous Injection of IBI112 in the Treatment of Moderate to Severe Plaque Psoriasis.

Last checked: Nov 19, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 566 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

566

Actual

Start

Oct 10, 2023

Primary completion

Apr 29, 2025

Study completion Jul 28, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of IBI112 in the treatment of participants with moderate to severe psoriasis

Conditions

  • Psoriasis

Interventions

  • IBI112Drug

    Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44

  • IBI112/placeboDrug

    Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection

  • IBI112/placeboDrug

    Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44

  • IBI112Drug

    Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44

  • IBI112Drug

    Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44

  • IBI112Drug

    Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 ResponseTime frame: Week 56

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.